Compare HOUR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOUR | IFRX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 60.6M |
| IPO Year | 2021 | 2017 |
| Metric | HOUR | IFRX |
|---|---|---|
| Price | $1.90 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 10.8K | ★ 178.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.57 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $138,252,861.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $27.40 | ★ N/A |
| Revenue Growth | ★ 4.64 | N/A |
| 52 Week Low | $1.10 | $0.71 |
| 52 Week High | $6.84 | $1.94 |
| Indicator | HOUR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 56.15 |
| Support Level | $1.74 | $0.96 |
| Resistance Level | $1.95 | $1.16 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 9.09 | 82.45 |
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.